Prepn process and medicinal composition of amorphous Adefovir dipivoxil

An adefovir dipivoxil and amorphous technology, applied in the field of amorphous 9-[2[[bismethoxy]phosphinyl]methoxyethyl adenine, can solve the preparation of amorphous adefovir dipivoxil Complicated methods, unfavorable industrial production, high equipment requirements, etc., achieve the effect of low price, easy access to auxiliary materials, and lower production process requirements

Active Publication Date: 2008-09-10
江苏吴中苏药医药开发有限责任公司 +1
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Existing amorphous adefovir dipivoxil preparation methods are all more complicated, loaded down with trivial details, all want low-temperature freezing, equipment requirement is high, and cost is high, is unfavorable for suitability for industrialized production, as Chinese patent CN1374314A ("adefovir dipivoxil amorphous solidified substance and preparation method"), Chinese patent CN1621408A ("a preparation method of amorphous adefovir dipivoxil") and Chinese patent CN1670025A ("a preparation method of amorphous adefovir dipivoxil") are all like this

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1: Preparation of amorphous adefovir dipivoxil

[0024] Add 10 g of oily adefovir dipivoxil, add 10 g of dichloromethane to dissolve at 20°C, evaporate to dryness under reduced pressure at 20°C to obtain an amorphous powder, put it in a vacuum oven and dry it under vacuum at 20°C to obtain a white amorphous powder.

Embodiment 2

[0025] Embodiment 2: Preparation of amorphous adefovir dipivoxil

[0026] Add 20 g of chloroform to dissolve 10 g of crystalline adefovir dipivoxil at 35°C, evaporate to dryness under reduced pressure at 35°C to obtain an amorphous powder, and dry it in a vacuum oven at 30°C to obtain a white amorphous powder.

Embodiment 3

[0027] Embodiment 3: Preparation of amorphous adefovir dipivoxil

[0028] Add 10 g of oily adefovir dipivoxil, add 30 g of methanol to dissolve at 40°C, evaporate to dryness under reduced pressure at 40°C to obtain an amorphous powder, put it in a vacuum oven and dry it under vacuum at 40°C to obtain a white amorphous powder.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to preparation process and medicinal composition of amorphous Adeforvir dipivolxil. The amorphous Adeforvir dipivolxil preparing process includes the following steps: adding pure crystalline or oily Adeforvir dipivolxil into organic solvent with the weight ratio between Adeforvir dipivolxil and organic solvent being 1 to 1-20, dissolving at 20-80 deg.c, decompression evaporating at 20-80 deg.c to obtain foamed solid, and final vacuum drying at 20-40 deg.c. The amorphous Adeforvir dipivolxil as effective component in 2-50 wt% is further mixed with excipient(s) in 50-98 wt% to produce medicinal composition of Adeforvir dipivolxil.

Description

technical field [0001] The present invention relates to the preparation method of amorphous 9-[2[[bis(pivaloyloxy)methoxy]phosphinyl]methoxyethyladenine, whose common name is adefovir dipivoxil (AD), and its containing Pharmaceutical composition of amorphous adefovir dipivoxil. Background technique [0002] Adefovir dipivoxil is a broad-spectrum antiviral drug. It is a polymerase inhibitor and a reverse transcriptase inhibitor. It has antagonism activity against many viruses, including HIV (AIDS virus), HBV (hepatitis B virus), HCMV (human Cytomegalovirus), HSV-I, II (herpes virus type I, II), MSV (Moloney murine sarcoma virus), FLV (hemophilia leukemia virus). [0003] Clinical trials have shown that adefovir dipivoxil has high anti-chronic hepatitis B virus (HBV) DNA activity, and can reduce the hepatitis B e antigen in blood and seroconversion, and is resistant to lamivudine and famciclovir. Serial HBV still has anti-activity, and its own drug resistance is small. In S...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07F9/6561A61K31/675A61K9/20A61K9/48A61K47/38A61P31/12A61P1/16
Inventor 周勤武卫徐成张荣久曹庆先
Owner 江苏吴中苏药医药开发有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap